Loading
A phase 2 trial of Telisotuzumab adizutecan, Fluorouracil, CAPOX in colorectal cancer, run by AbbVie, now recruiting.
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT06820463 by AbbVie, with 390 participants planned, started 2025-04-24 and due to reach its primary completion in 2028-03. Interventions recorded: Telisotuzumab Adizutecan, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Fluorouracil (5-FU), Bevacizumab.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Colorectal cancer.
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Bevacizumab.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Fluorouracil (5-FU), Bevacizumab, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Bevacizumab, Colorectal cancer.